HRP20150450T1 - Spojevi aril triazola sa antitumorskom aktivnošä†u - Google Patents

Spojevi aril triazola sa antitumorskom aktivnošä†u Download PDF

Info

Publication number
HRP20150450T1
HRP20150450T1 HRP20150450TT HRP20150450T HRP20150450T1 HR P20150450 T1 HRP20150450 T1 HR P20150450T1 HR P20150450T T HRP20150450T T HR P20150450TT HR P20150450 T HRP20150450 T HR P20150450T HR P20150450 T1 HRP20150450 T1 HR P20150450T1
Authority
HR
Croatia
Prior art keywords
phenyl
isopropyl
dihydroxy
ylmethyl
triazole
Prior art date
Application number
HRP20150450TT
Other languages
English (en)
Croatian (hr)
Inventor
Giuseppe Giannini
Walter Cabri
Loredana Vesci
Maria Luisa CERVONI
Claudio Pisano
Maurizio Taddei
Serena FERRINI
Original Assignee
Sigma-Tau Research Switzerland S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Research Switzerland S.A. filed Critical Sigma-Tau Research Switzerland S.A.
Publication of HRP20150450T1 publication Critical patent/HRP20150450T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HRP20150450TT 2010-12-20 2011-12-13 Spojevi aril triazola sa antitumorskom aktivnošä†u HRP20150450T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195949 2010-12-20
PCT/EP2011/072558 WO2012084602A1 (en) 2010-12-20 2011-12-13 Aryl triazole compounds with antitumoural activity
EP11805449.3A EP2655345B1 (en) 2010-12-20 2011-12-13 Aryl triazole compounds with antitumoural activity

Publications (1)

Publication Number Publication Date
HRP20150450T1 true HRP20150450T1 (hr) 2015-06-05

Family

ID=43901588

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150450TT HRP20150450T1 (hr) 2010-12-20 2011-12-13 Spojevi aril triazola sa antitumorskom aktivnošä†u

Country Status (16)

Country Link
US (1) US9302998B2 (enExample)
EP (1) EP2655345B1 (enExample)
JP (1) JP2014501232A (enExample)
AR (1) AR084361A1 (enExample)
CY (1) CY1116297T1 (enExample)
DK (1) DK2655345T3 (enExample)
ES (1) ES2536980T3 (enExample)
HR (1) HRP20150450T1 (enExample)
HU (1) HUE025697T2 (enExample)
ME (1) ME02144B (enExample)
PL (1) PL2655345T3 (enExample)
PT (1) PT2655345E (enExample)
RS (1) RS53966B1 (enExample)
SI (1) SI2655345T1 (enExample)
SM (1) SMT201500115B (enExample)
WO (1) WO2012084602A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6027244B2 (ja) * 2012-09-17 2016-11-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリアゾールカルボキサミド誘導体
CN103275023B (zh) * 2013-06-08 2015-10-07 浙江工业大学 1-芳基-1,2,3-三氮唑类化合物及其制备和应用
CN107540624B (zh) * 2016-06-29 2020-06-16 广州市恒诺康医药科技有限公司 热休克蛋白抑制剂及其制备方法和应用
US10975030B2 (en) 2016-10-31 2021-04-13 University Of Kansas Grp94 selective inhibitors and uses thereof
WO2019040869A1 (en) * 2017-08-25 2019-02-28 The Trustees Of Columbia University In The City Of New York INHIBITORS OF IMPORTS OF PURINE IN PARASITES AND USES OF THESE INHIBITORS
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110590686B (zh) * 2019-10-31 2022-10-25 重庆大学 一种氮杂糖基1,2,3-三氮唑核苷化合物及其制备方法和应用
WO2021137665A1 (ko) * 2019-12-30 2021-07-08 이화여자대학교 산학협력단 Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10315570A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Triazolderivate
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2006109846A1 (ja) 2005-04-06 2006-10-19 Takeda Pharmaceutical Company Limited トリアゾール誘導体およびその用途
JP2006306755A (ja) * 2005-04-27 2006-11-09 Nippon Kayaku Co Ltd 新規なピラゾール誘導体とそれを有効成分とするhsp90阻害剤
AU2006272652B2 (en) * 2005-07-25 2011-06-16 Synta Pharmaceuticals Corp. 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
CN101679319B (zh) * 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
US20110065725A1 (en) 2008-03-18 2011-03-17 Glaxo Group Limited Triazole amide derivatives for use in therapy
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2009139916A1 (en) 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
TW201011003A (en) * 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
ES2415234T3 (es) 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90

Also Published As

Publication number Publication date
ES2536980T3 (es) 2015-06-01
EP2655345B1 (en) 2015-02-18
JP2014501232A (ja) 2014-01-20
ME02144B (me) 2015-10-20
HUE025697T2 (en) 2016-04-28
DK2655345T3 (en) 2015-05-04
AR084361A1 (es) 2013-05-08
PT2655345E (pt) 2015-06-09
SI2655345T1 (sl) 2015-06-30
CY1116297T1 (el) 2017-02-08
WO2012084602A1 (en) 2012-06-28
SMT201500115B (it) 2015-07-09
US20140329812A1 (en) 2014-11-06
PL2655345T3 (pl) 2015-07-31
RS53966B1 (sr) 2015-08-31
US9302998B2 (en) 2016-04-05
EP2655345A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
HRP20150450T1 (hr) Spojevi aril triazola sa antitumorskom aktivnošä†u
JP7605892B2 (ja) Tead転写因子の新規小分子阻害剤
ES2536191T3 (es) Derivados de sulfonamida
JP2014501232A5 (enExample)
AU2017351688B2 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH
JP4101852B2 (ja) シンナミド化合物
JP6424219B2 (ja) 複素芳香環−ベンジル−アミド−サイクルコアを含むオートタキシン阻害剤
ES2532357T3 (es) Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
EA010132B1 (ru) Производные триазола в качестве антагонистов вазопрессина
JP2009507080A5 (enExample)
JP2014511869A5 (enExample)
ES2618812T3 (es) Antagonistas del receptor mineralocorticoide
DK3083564T3 (en) Heteroberl butyric acid derivatives as LTA4H inhibitors
JP2015529192A5 (enExample)
JP2007039461A5 (enExample)
RU2015138964A (ru) Полициклические модуляторы рецептора эстрогена и их применения
JPWO2020190774A5 (enExample)
CA2551788A1 (en) Novel carboxamides for use as xa inhibitors
HRP20160421T1 (hr) Derivat azola
CA2907528A1 (en) Novel compounds
ES2541289T3 (es) Compuestos de pirazol que tienen un efecto terapéutico sobre mieloma múltiple
RU2008105761A (ru) 4-5-дигидро-1н-пиразольные производные, их получение и применение в качестве лекарственного средства
RU2006135482A (ru) Терапевтические агенты
US20190218196A1 (en) Furane derivatives as inhibitors of atad2
WO2016131808A1 (en) 1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitorsof the wnt signalling pathway